Activators of peroxisome proliferator-activated receptors

Details Activators of peroxisome proliferator-activated receptors Activators of peroxisome proliferator-activated receptors

2007-08-27

2009-06-16

Weddington, Kevin E (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C514S866000

Reexamination Certificate

active

07547730

ABSTRACT:
Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient.

REFERENCES:
patent: 4346109 (1982-08-01), Yamatsu et al.
patent: 4491592 (1985-01-01), Katoh et al.
patent: 4655973 (1987-04-01), Yamatsu et al.
patent: 4757140 (1988-07-01), DeLuca et al.
patent: 4788330 (1988-11-01), Nakamoto et al.
patent: 4841038 (1989-06-01), DeLuca et al.
patent: 4883916 (1989-11-01), Nakamoto et al.
patent: 4888439 (1989-12-01), Yamatsu et al.
patent: 4917829 (1990-04-01), Yamatsu et al.
patent: 5852057 (1998-12-01), Muto et al.
patent: 6369251 (2002-04-01), Takano et al.
patent: 6984742 (2006-01-01), Tanikawa et al.
patent: 2005/0250671 (2005-11-01), Shidoji et al.
patent: 2006/0094784 (2006-05-01), Kagawa et al.
patent: 781809 (1957-08-01), None
patent: 054732 (1982-06-01), None
patent: 0107188 (1984-05-01), None
patent: 194693 (1986-09-01), None
patent: 0847754 (1998-06-01), None
patent: 1046630 (2003-03-01), None
patent: 2073750 (1981-10-01), None
patent: 54-046821 (1979-04-01), None
patent: 55-22645 (1980-02-01), None
patent: 55-138457 (1980-10-01), None
patent: 58-109415 (1983-06-01), None
patent: 62-77317 (1987-04-01), None
patent: 63-32058 (1988-06-01), None
patent: 6332058 (1988-06-01), None
patent: 63-166824 (1988-07-01), None
patent: 6334855 (1988-07-01), None
patent: 10-167960 (1998-06-01), None
patent: 2000 122974 (2000-04-01), None
patent: 94/22818 (1994-10-01), None
patent: 01/15702 (2001-03-01), None
patent: 01/80854 (2001-11-01), None
patent: 03/097034 (2003-11-01), None
patent: 2004/017958 (2004-03-01), None
U.S. Appl. No. 10/524,420, to Reiko Kawamura et al., filed Aug. 19, 2003.
Nariaki Nakamura et al., “Apoptosis in Human Hepatoma Cell Line Induced by 4,5-Didehydrogeranylgeranoic Acid (Acyclic Retinoid) Via Down-Regulation of Transforming Growth Factor-α,” Biochemical and Biophysical Research Communications, vol. 219, No. 1, pp. 100-104 (1996).
M. Okuno et al., “Retinoids Exacerbate Rat Liver Fibrosis by Inducing the Activation of latent TGF-β in Liver Stellate Cells,” Hepatology (Philadelphia), vol. 26, No. 4, pp. 913-921 (1997).
Di Bisceglie A.M. et al., “Hepatocellular Carcinoma,” Hepatology, vol. 28, No. 4, pp. 1161-1165 (1998).
Ishiwari, K., “The Effects of a Synthetic Retinoid on Phenotypic Expression of Cultured Mesangial Cells,” Kyoto-furitsu Ika Daigaku Zasshi, vol. 106, No. 3, pp. 273-283 (1997).
English language Abstract of JP 56-140949.
English language Abstract of JP 10-167960.
English language Abstract of JP 54-046821.
English language Abstract of JP 55-22645.
English language Abstract of JP 58-109415.
English language Abstract of JP62-77317.
English language Abstract of JP63-166824.
Yasutoshi Muto, et al., “Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma” New Eng. J. Med., vol. 340, No. 13, pp. 1046-1047 (1999).
K. Tago et al., “A Practical Total Synthesis of Plaunotol via Highly Z-selective Wittig Olefination of α-acetal ketones,” J. Chem. Soc. Perkin Trans. 1, pp. 2073-2078 (2000).
W.C. Still et al., “Direct Synthesis of Z-Unsaturated Esters. A Useful Modification of the Horner-Emmons Olefination,” Tetrahedron Letters, vol. 24, No. 41, pp. 4405-4408 (1983).
T. Kajiwara et al., “Steroselective Synthesis of Ectocarpene and Its Antipode via Microbiological Asymmetric Hydrolysis,” Agric. Biol. Chem., vol. 45, pp. 1461-1466 (1981).
Chinese Journal of Applied Chemistry, vol. 5, 1988, pp. 70-71.
R. Boden, “A Mild Method for Preparing trans-Alkenes; Crown Ether Catalysis of the Wittig Reaction,” Synthesis, p. 784 (1975).
G. Bellucci et al., “Crown Ether Catalyzed Stereospecific Synthesis of Z- and E-Stilbenes by Wittig Reaction in a Solid-Liquid Two-Phases System,” Tetrahedron Letters, vol. 37, No. 24, pp. 4225-4228 (1996).
M. Mikolajczyk et al., “Synthesis of α,β-Unsaturated Sulphides, Sulphoxides, and Sulphones by the Horner-Wittig Reaction in Two-Phase System Catalysed by Quaternary Ammonium Salts and Crown Ethers,” Synthesis, pp. 278-280 (1975).
Izv. Akad. Nauk SSSR, Khim., 1990, pp. 2544-2550.
Izv. Akad. Nauk SSSR, Khim., 1988, pp. 2382-2385.
Izv. Akad. Nauk SSSR, Khim., 1988, pp. 2377-2382.
R.N. Gedye et al., “The Stereochemistry of the Wittig Reactions of Allylic Phosphroranes and Phosponate Esters with Aldehydes,” Can. J. Chem., vol. 55, pp. 1218-1228 (1977).
K. Ashizawa et al., “The Crystal Structure of 3,7,11,15-Tetramethyl-2,4,6,10,14- All Trans-Hexadecapentaenoic Acid (E-5166),” Chem. Pharm. Bull., vol. 33, No. 7, pp. 3062-3064 (1985).
English Language Abstract of JP 57-106638 corresponding to JP Appln. No. 63-34855.
English Language Abstract of JP 56-140949 corresponding to JP Appln. No. 63-32058.
Reaven, G.M., Diabetes, vol. 37, pp. 1595-1607 (1988).
Issemann, I., et al., Nature, vol. 347, pp. 645-650, 1990.
Lehmann, J.M., et al., J. Biol. Chem. vol. 270, pp. 12953-12956, 1995.
Saltiel, A.R., et al., Diabetes, vol. 45, pp. 1661-1669, 1996.
Rinshu Iyaku., et al., vol. 14, pp. 461-466, 1998.
Muto, Y., et al., N. Eng. J. Med., 334,pp. 1561-1567, 1996.
Davis, J.B., et al., J. Chem. Soc (C), pp. 2154-2165, 1966.
Ellinghaus, P., et al., J. Biol. Chem., vol. 274, No. 5, pp. 2766-2772 (1999).
Kliewer, S.A., et al., Proc. Natl. Acad. Sci. U.S.A., vol. 94, No. 9, pp. 4318-4323 (1997).
Göttlicher, M., et al., Biochem. Pharmacol., vol. 46, No. 12, pp. 2177-2184 (1993).
Issemann, I., et al., J. Mol. Endocrinol., vol. 11, No. 1, pp. 37-47 (1993).
Remngton: The Science and Practice of Pharmacy, Mack Publishing Co., Nineteenth Edition , vol. 1(1995), Chapter 48, “The Introduction of New Drugs”, pp. 795-808.
Http://www.truestarthealth.com /Notes/1028005.htm (2007) High Cholesterol.

Affiliated with

Also associated with

Rating

Activators of peroxisome proliferator-activated receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Activators of peroxisome proliferator-activated receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activators of peroxisome proliferator-activated receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4131003